ATE478688T1 - Verbindungen für den transfer von oligonukleotiden - Google Patents

Verbindungen für den transfer von oligonukleotiden

Info

Publication number: ATE478688T1
Authority: AT; Austria
Prior art keywords: oligonucleotides; compounds; transfer; collagen; preparations
Prior art date: 2000-06-20

Application number

AT01938732T

Other languages

English (en)

Inventor

Shunichiro Kubota

Masaaki Terada

Takahiro Ochiya

Hiroshi Itoh

Masayasu Furuse

Akihiko Sano

Shunji Nagahara

Original Assignee

Dainippon Sumitomo Pharma Co

Koken Kk

Nat Cancer Ct

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-20

Filing date

2001-06-19

Publication date

2010-09-15

2001-06-19 Application filed by Dainippon Sumitomo Pharma Co, Koken Kk, Nat Cancer Ct filed Critical Dainippon Sumitomo Pharma Co

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE478688T1 publication Critical patent/ATE478688T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title 1
102000008186 Collagen Human genes 0.000 abstract 1
108010035532 Collagen Proteins 0.000 abstract 1
210000004102 animal cell Anatomy 0.000 abstract 1
230000000692 anti-sense effect Effects 0.000 abstract 1
229920001436 collagen Polymers 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

AT01938732T 2000-06-20 2001-06-19 Verbindungen für den transfer von oligonukleotiden ATE478688T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2000184502		2000-06-20
PCT/JP2001/005195 WO2001097857A1 (fr)	2000-06-20	2001-06-19	Preparations destinees au transfert d'oligonucleotides

Publications (1)

Publication Number	Publication Date
ATE478688T1 true ATE478688T1 (de)	2010-09-15

Family

ID=18684937

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01938732T ATE478688T1 (de)	2000-06-20	2001-06-19	Verbindungen für den transfer von oligonukleotiden

Country Status (10)

Country	Link
US (3)	US20040052840A1 (de)
EP (1)	EP1295611B1 (de)
JP (1)	JP5118285B2 (de)
AT (1)	ATE478688T1 (de)
AU (1)	AU2001264317A1 (de)
DE (1)	DE60142899D1 (de)
DK (1)	DK1295611T3 (de)
ES (1)	ES2349137T3 (de)
PT (1)	PT1295611E (de)
WO (1)	WO2001097857A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW586934B (en) *	1997-05-19	2004-05-11	Sumitomo Pharma	Immunopotentiating composition
AU2001264317A1 (en) *	2000-06-20	2002-01-02	Koken Co., Ltd.	Preparations for oligonucleotide transfer
EP1407787B1 (de)	2001-06-20	2009-04-29	Dainippon Sumitomo Pharma Co., Ltd.	Verfahren zur förderung des nukleinsäuretransfers
US20100104631A1 (en) *	2001-08-13	2010-04-29	Lipella Pharmaceuticals Inc.	Method of treatment for bladder dysfunction
WO2004026343A1 (ja) *	2002-09-20	2004-04-01	Sumitomo Phamaceuticals Co., Ltd.	部位特異的遺伝子変換促進剤および遺伝子疾患治療剤
WO2005061717A1 (ja) *	2003-12-19	2005-07-07	Dainippon Sumitomo Pharma Co., Ltd.	新規な核酸導入法
US20090062184A1 (en) *	2005-03-24	2009-03-05	Dainippon Sumitomo Pharma Co., Ltd.	Fine particulate preparation comprising complex of nucleic acid molecule and collagen
US7838502B2 (en) *	2005-05-06	2010-11-23	University Of Massachusetts Medical School	Compositions and methods to modulate H. influenzae pathogenesis
ES2405357T3 (es) *	2005-05-25	2013-05-30	Cellmid Limited	Composición farmacéutica para la vasculopatía oclusiva.
KR100777249B1 (ko) *	2006-02-14	2007-11-28	(주)바이오니아	건조 올리고뉴클레오티드 조성물 및 이의 제조 방법
WO2010078403A2 (en) *	2008-12-30	2010-07-08	Lipella Pharmaceuticals Inc.	Methods and compositions for diagnosing urological disorders
FR3066115B1 (fr) *	2017-05-10	2019-06-28	Universite de Bordeaux	Comprimes de vecteurs d'acides nucleiques
MX2021015539A (es) *	2019-07-02	2022-02-10	Hoffmann La Roche	Proceso para la preparacion de productos del tipo de alta hidrofilia con humedad controlada.

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5115094B2 (de) *	1972-11-01	1976-05-14
US5069936A (en) *	1987-06-25	1991-12-03	Yen Richard C K	Manufacturing protein microspheres
US5078997A (en) *	1988-07-13	1992-01-07	Cetus Corporation	Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5098890A (en) *	1988-11-07	1992-03-24	Temple University-Of The Commonwealth System Of Higher Education	Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5614587A (en) *	1988-11-21	1997-03-25	Collagen Corporation	Collagen-based bioadhesive compositions
US5936035A (en) *	1988-11-21	1999-08-10	Cohesion Technologies, Inc.	Biocompatible adhesive compositions
JP3187410B2 (ja) *	1989-08-10	2001-07-11	住友製薬株式会社	脳内投与用徐放性製剤
US5542935A (en) *	1989-12-22	1996-08-06	Imarx Pharmaceutical Corp.	Therapeutic delivery systems related applications
US5264618A (en) *	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
FR2694895B1 (fr) *	1992-08-20	1994-11-10	Coletica	Procédé de fabrication de microparticules en émulsion par modification de la composition chimique de la phase dispersée après émulsification.
US5646042A (en) *	1992-08-26	1997-07-08	Ribozyme Pharmaceuticals, Inc.	C-myb targeted ribozymes
WO1994028014A2 (en) *	1993-05-28	1994-12-08	Chiron Corporation	Peptide inhibitors of urokinase receptor activity
AU7655194A (en) *	1993-09-09	1995-03-27	Schering Aktiengesellschaft	Active principles and gas containing microparticles
CA2140053C (en) *	1994-02-09	2000-04-04	Joel S. Rosenblatt	Collagen-based injectable drug delivery system and its use
US5942496A (en) *	1994-02-18	1999-08-24	The Regent Of The University Of Michigan	Methods and compositions for multiple gene transfer into bone cells
US5583034A (en) *	1994-02-22	1996-12-10	La Jolla Institute For Allergy And Immunology	Enhancement of adoptosis using antisense oligonucleotides
US5844107A (en) *	1994-03-23	1998-12-01	Case Western Reserve University	Compacted nucleic acids and their delivery to cells
US5563255A (en) *	1994-05-31	1996-10-08	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of raf gene expression
JPH11505505A (ja) *	1994-06-27	1999-05-21	ザ・ジョンズ・ホプキンス・ユニバーシティー	ターゲッティングされた遺伝子輸送システム
WO2001074342A2 (en) *	2000-03-31	2001-10-11	Trustees Of Boston University	Use of locally applied dna fragments
US6998268B2 (en) *	1995-07-03	2006-02-14	Dainippon Sumitomo Pharma Co. Ltd.	Gene preparations
JP3867160B2 (ja) *	1995-07-03	2007-01-10	大日本住友製薬株式会社	遺伝子製剤
IL122802A0 (en) *	1995-07-03	1998-08-16	Koken Kk	Gene preparations
CA2235685A1 (en) *	1995-10-23	1997-05-01	Hyal Pharmaceutical Australia Limited	Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
WO1997022371A1 (en) *	1995-12-18	1997-06-26	Collagen Corporation	Crosslinked polymer compositions and methods for their use
WO1997033998A1 (en) *	1996-03-14	1997-09-18	The Immune Response Corporation	Targeted delivery of genes encoding interferon
US6133437A (en) *	1997-02-13	2000-10-17	Apoptogen, Inc.	Modulation of IAPs for the treatment of proliferative diseases
US5874006A (en) *	1996-10-31	1999-02-23	Matrix Pharmaceutical, Inc.	Aseptic collagen concentration process
US6042820A (en) *	1996-12-20	2000-03-28	Connaught Laboratories Limited	Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6218112B1 (en) *	1996-12-23	2001-04-17	Cobra Therapeutics Limited	Optimization of gene delivery and gene delivery system
EP2319854B1 (de) *	1997-01-08	2016-11-30	Sigma-Aldrich Co. LLC	Biokonjugation von Makromolekülen
US6524613B1 (en) *	1997-04-30	2003-02-25	Regents Of The University Of Minnesota	Hepatocellular chimeraplasty
WO1999040771A2 (en) *	1998-02-13	1999-08-19	Selective Genetics, Inc.	Concurrent flow mixing for preparing compositions comprising gene therapy vectors
US7052875B1 (en) *	1998-05-22	2006-05-30	Sumitomo Pharmaceutical Company, Limited	Stable gene preparations
AU2001264317A1 (en) *	2000-06-20	2002-01-02	Koken Co., Ltd.	Preparations for oligonucleotide transfer
JP2002325572A (ja) *	2000-12-25	2002-11-12	Univ Osaka	外来物質の導入方法
EP1407787B1 (de) *	2001-06-20	2009-04-29	Dainippon Sumitomo Pharma Co., Ltd.	Verfahren zur förderung des nukleinsäuretransfers
US7148342B2 (en) *	2002-07-24	2006-12-12	The Trustees Of The University Of Pennyslvania	Compositions and methods for sirna inhibition of angiogenesis
EP1551424B1 (de) *	2002-09-04	2015-07-01	Arrowhead Research Corporation	Behandlung von chronisch neuropathischen schmerzen durch verabreichung von dsrna
WO2004026343A1 (ja) *	2002-09-20	2004-04-01	Sumitomo Phamaceuticals Co., Ltd.	部位特異的遺伝子変換促進剤および遺伝子疾患治療剤
NZ540779A (en) *	2002-11-01	2008-05-30	Univ Pennsylvania	Compositions and methods for siRNA inhibition of HIF-1 alpha
JP2007524349A (ja) *	2003-01-16	2007-08-30	ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア	ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法
US8227434B1 (en) *	2003-11-04	2012-07-24	H. Lee Moffitt Cancer Center & Research Institute, Inc.	Materials and methods for treating oncological disorders
EP1720893B1 (de) *	2004-02-26	2014-08-13	Baylor Research Institute	Zusammensetzungen und verfahren zur systemischen behandlung von arthritis
AU2005288522B2 (en) *	2004-09-28	2012-06-28	Quark Pharmaceuticals, Inc.	Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
WO2006042396A1 (en) *	2004-10-22	2006-04-27	Universite Laval	Modulation of neuroglia-derived bdnf in the treatment and prevention of pain
US7585848B2 (en) *	2005-01-11	2009-09-08	Rush University Medical Center	Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
WO2007082899A1 (en) *	2006-01-17	2007-07-26	Vib Vzw	Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
EP2047864B1 (de) *	2006-06-16	2017-04-05	Taisho Pharmaceutical Co., Ltd.	Verwendung von rpn2-gen-expressionshemmer
KR101670085B1 (ko) *	2006-07-21	2016-10-28	사일런스 테라퓨틱스 게엠베하	단백질 키나아제 3의 발현을 억제하기 위한 수단
US7825101B2 (en) *	2006-08-30	2010-11-02	The Board Of Trustees Of The University Of Illinois	Modulation of MLCK-L expression and uses thereof
US7902167B2 (en) *	2006-10-02	2011-03-08	Aprea Ab	Compounds and methods for down-regulating Wrap53 protein by RNA interference
US7812002B2 (en) *	2007-03-21	2010-10-12	Quark Pharmaceuticals, Inc.	Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
US8227444B2 (en) *	2009-12-04	2012-07-24	Opko Ophthalmics, Llc	Compositions and methods for inhibition of VEGF

2001
- 2001-06-19 AU AU2001264317A patent/AU2001264317A1/en not_active Abandoned
- 2001-06-19 JP JP2002503340A patent/JP5118285B2/ja not_active Expired - Fee Related
- 2001-06-19 DK DK01938732.3T patent/DK1295611T3/da active
- 2001-06-19 EP EP01938732A patent/EP1295611B1/de not_active Expired - Lifetime
- 2001-06-19 AT AT01938732T patent/ATE478688T1/de active
- 2001-06-19 PT PT01938732T patent/PT1295611E/pt unknown
- 2001-06-19 DE DE60142899T patent/DE60142899D1/de not_active Expired - Lifetime
- 2001-06-19 ES ES01938732T patent/ES2349137T3/es not_active Expired - Lifetime
- 2001-06-19 WO PCT/JP2001/005195 patent/WO2001097857A1/ja not_active Ceased
- 2001-06-19 US US10/311,621 patent/US20040052840A1/en not_active Abandoned
2009
- 2009-06-17 US US12/486,703 patent/US20090258933A1/en not_active Abandoned
2010
- 2010-10-13 US US12/904,054 patent/US20110028535A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2001097857A1 (fr)	2001-12-27
EP1295611A1 (de)	2003-03-26
JP5118285B2 (ja)	2013-01-16
US20110028535A1 (en)	2011-02-03
EP1295611B1 (de)	2010-08-25
US20040052840A1 (en)	2004-03-18
DE60142899D1 (de)	2010-10-07
DK1295611T3 (da)	2010-10-04
ES2349137T3 (es)	2010-12-28
US20090258933A1 (en)	2009-10-15
PT1295611E (pt)	2010-09-14
EP1295611A4 (de)	2009-07-08
AU2001264317A1 (en)	2002-01-02

Legal Events

Date

Code

Title

Description

2011-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1295611

Country of ref document: EP

Publication	Publication Date	Title
CY1123084T1 (el)	2021-10-29	Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
EP1325019A4 (de)	2006-09-20	Antisense-modulation der clusterinexpression
ATE305788T1 (de)	2005-10-15	(s,s)-reboxetin zur behandlung von inkontinenz
EP1250455A4 (de)	2004-09-29	Antisense inhibierung der ptp1b expression.
TW200502385A (en)	2005-01-16	Modulation of forkhead box o1a expression
WO2002036743A3 (en)	2003-01-16	Antisense modulation of calreticulin expression
EP1417351A4 (de)	2005-06-01	Antisense-modulation der expression von apolipoprotein(a)
ATE478688T1 (de)	2010-09-15	Verbindungen für den transfer von oligonukleotiden
DE3782214D1 (de)	1992-11-19	Mittel zur behandlung des scheidenmilieus.
EP1648910A4 (de)	2008-02-27	Antisense-modulation der expression von stearoyl coa desaturase
WO2001029175A3 (en)	2001-10-11	Antisense modulation of fra-1 expression
EP1218398A4 (de)	2004-09-08	Antisense-modulation von pi3-kinase p110 beta-expression
EP1250347A4 (de)	2004-03-17	Antisense modulation der akt-3 expression
DE50009838D1 (de)	2005-04-28	Humanes antibiotisches protein
MXPA02012857A (es)	2004-07-30	Uso de una formulacion elaborada de o que contiene al menos un suero de leche dismilado.
ATE344662T1 (de)	2006-11-15	Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DK1359943T3 (da)	2006-01-02	Biotinderivater og deres konjugater med chelateringsmidler
WO2002024864A3 (en)	2002-05-30	Antisense modulation of syntaxin 4 interacting protein expression
WO2002041836A3 (en)	2002-08-29	Antisense modulation of src-1 expression
WO2003040320A3 (en)	2004-08-19	Antisense modulation of human collapsin response mediator protein 2 expression
EP1373291A4 (de)	2005-03-16	Antisense-modulierung der recql4 expression
ZA200103603B (en)	2001-12-06	Treatment of animal hides.
UA38418A (uk)	2001-05-15	Засіб для стимуляції регенеративних процесів в інсулінпродукуючому апараті підшлункової залози
WO2002044325A3 (en)	2002-08-22	Antisense modulation of src-1 expression
ITBO990456A0 (it)	1999-08-12	Metodo per il trattamento del terreno .